Farallon Capital Management 13F: Cuts BBNX Stake by $11M

Farallon Capital Management Trims Beta Bionics Stake

Farallon Capital Management lowered its exposure to Beta Bionics, Inc. BBNX by shedding 706,000 shares during the period. The quarterly SEC filing shows the firm wrapped up the reporting window with 3,607,920 shares remaining in the medical device maker. That reduction translated to a 16.4% decrease from its prior count of 4,313,920 shares. Based on the valuation provided in the disclosure, the remaining block was worth roughly $56.5 million.

Beta Bionics Stock Context

Shares of Beta Bionics traded hands at $15.67. The company carries a market capitalization of $1.16 billion and is not currently profitable, meaning it has no positive price-to-earnings ratio. Its stock price sits below its 50-day moving average of $17.71 while tracking above its 200-day moving average of $16.22. Over the past year, the shares have traded as low as $8.80 and as high as $32.71.

Recent Earnings

Beta Bionics generated $119.0 million in revenue over the tracked timeframe, alongside a revenue growth rate of 37.8%. The company posted a net margin of -61.3% and a return on equity of -26.2%, with earnings per share coming in at -$1.60. The medical device firm is scheduled to release its next round of financial results on October 27, 2026.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the medical device developer through recent months. On August 21, 2026, William Blair initiated coverage on the stock with a Market Perform rating and no price target. Later, Leerink Partners maintained an Outperform rating while lifting its target from $24.00 to $27.00 on September 14, 2026. Baird kept a Neutral rating while raising its target from $14.00 to $16.00 on September 15, 2026. B of A Securities maintained a Neutral rating and lifted its target from $18.00 to $20.00 on the same day. Truist Securities reiterated a Buy rating and moved its target from $22.00 to $23.00 on September 15, 2026, and later maintained a Buy rating while raising its target from $23.00 to $28.00 on September 24, 2026. Wells Fargo initiated an Overweight rating with a $28.00 target on September 23, 2026. Jefferies also initiated coverage with a Buy rating and a $30.00 target on October 12, 2026. Overall, the company holds a consensus buy recommendation and a mean price target of $22.40 from 11 analysts.

About Beta Bionics

Beta Bionics, Inc. is a medical device enterprise based in Irvine, California. The company designs and commercializes automated insulin delivery systems for people with diabetes, including the iLet Bionic Pancreas and developmental patch pump solutions designed to simplify blood sugar management for adults and children.

What's Ahead for Beta Bionics, Inc.

Institutional 13F filings offer a backward-looking view of portfolio adjustments made as of the end of the reporting period and do not necessarily reflect current holdings. Investors tracking Farallon Capital Management and Beta Bionics will look to upcoming earnings reports and subsequent regulatory filings for further updates on institutional sentiment.